Next Article in Journal
Regression of Follicular Lymphoma With Devil’s Claw: Coincidence or Causation?
Previous Article in Journal
Radiotherapy for Oncologic Emergencies on Weekends: Examining Reasons for Treatment and Patterns of Practice at a Canadian Cancer Centre
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

rna Interference and micro-rna–Oriented Therapy in Cancer: Rationales, Promises, and Challenges

1
Goodman Cancer Centre and Department of Biochemistry, McGill University, Montreal, QC, Canada
2
Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(4), 61-66; https://doi.org/10.3747/co.v16i4.486
Submission received: 6 May 2009 / Revised: 8 June 2009 / Accepted: 10 July 2009 / Published: 1 August 2009

Abstract

The discovery that rna interference (rnai) and its functional derivatives, small interfering rnas (sirnas) and micro-rnas (mirnas) could mediate potent and specific gene silencing has raised high hopes for cancer therapeutics. The prevalence of these small (18–25 nucleotide) non-coding rnas in human gene networks, coupled with their unique specificity, has paved the way for the development of new and promising therapeutic strategies in re-directing or inhibiting small rna phenomena. Three strategies are currently being developed: (1) De novo rnai programming using synthetic sirnas to target the expression of genes; (2) Strengthening or recapitulation of the physiologic targeting of messenger rnas by specific mirnas; (3) Sequence-specific inhibition of mirna functions by nucleic acid analogs. Each strategy, currently being developed both in academia and in industry, holds promise in cancer therapeutics.
Keywords: cancer therapy; sirna; mirna; rnai therapy; oncomirs; nucleic acid analogs; tumour-suppressor mirnas cancer therapy; sirna; mirna; rnai therapy; oncomirs; nucleic acid analogs; tumour-suppressor mirnas

Share and Cite

MDPI and ACS Style

Duchaine, T.F.; Slack, F.J. rna Interference and micro-rna–Oriented Therapy in Cancer: Rationales, Promises, and Challenges. Curr. Oncol. 2009, 16, 61-66. https://doi.org/10.3747/co.v16i4.486

AMA Style

Duchaine TF, Slack FJ. rna Interference and micro-rna–Oriented Therapy in Cancer: Rationales, Promises, and Challenges. Current Oncology. 2009; 16(4):61-66. https://doi.org/10.3747/co.v16i4.486

Chicago/Turabian Style

Duchaine, T. F., and F. J. Slack. 2009. "rna Interference and micro-rna–Oriented Therapy in Cancer: Rationales, Promises, and Challenges" Current Oncology 16, no. 4: 61-66. https://doi.org/10.3747/co.v16i4.486

Article Metrics

Back to TopTop